{"prompt": "['TABLE OF CONTENTS', 'Page', 'Clinical Intervention Study Protocol Template', '1', 'IMOVE: A randomized, controlled trial of Improvisational MOVEment for people with', 'memory loss and their caregivers', '2', 'Tool Revision History', '3', 'TABLE OF CONTENTS', '5', 'STUDY TEAM ROSTER', '8', 'PR\u00c9CIS', '10', '1. STUDY OBJECTIVES', '12', '1.1', 'Primary Objective', '12', '1.2', 'Secondary Objectives', '12', '2. BACKGROUND AND RATIONALE', '12', '2.1', 'Background on Condition, Disease, or Other Primary Study Focus', '12', '2.2', 'Study Rationale', '13', '3. STUDY DESIGN', '15', '4. SELECTION AND ENROLLMENT OF PARTICIPANTS', '16', '4.1', 'Inclusion Criteria', '17', '4.2', 'Exclusion Criteria', '18', '4.3', 'Study Enrollment Procedures', '20', '5. STUDY INTERVENTIONS', '23', '5.1', 'Interventions, Administration, and Duration', '23', '5.2', 'Handling of Study Interventions', '26', '5.3', 'Concomitant Interventions', '28', '5.3.1', 'Allowed Interventions', '28', '5.3.2', 'Required Interventions', '28', '5.3.3', 'Prohibited Interventions', '28', '5.4', 'Adherence Assessment', '29', '6. STUDY PROCEDURES', '29', '6.1', 'Schedule of Evaluations', '30', '6.2', 'Description of Evaluations', '32', 'IMOVE Protocol, Version 6.0', '5 of 76']['6.2.1', 'Screening Evaluation', '32', '6.2.2 Enrollment, Baseline, and/or Randomization', '33', '6.2.3', 'Blinding', '37', '6.2.4', 'Follow-up Visits', '37', '6.2.5', 'Completion/Final Evaluation', 'Error! Bookmark not defined.', '7. SAFETY ASSESSMENTS', '39', 'Alphabetical List of Expected Adverse Events for Study Interventions', '39', '7.1', 'Specification of Safety Parameters', '39', '7.2', 'Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters', '42', '7.3', 'Adverse Events and Serious Adverse Events', '42', '7.4', 'Reporting Procedures', '43', '7.5', 'Follow-up for Adverse Events', '44', '7.6', 'Safety Monitoring', '44', '8. INTERVENTION DISCONTINUATION', '44', '9. STATISTICAL CONSIDERATIONS', '45', '9.1', 'General Design Issues', '45', '9.2', 'Sample Size and Randomization', '47', 'Treatment Assignment Procedures', '48', '9.3', 'Definition of Populations', '49', '9.4', 'Interim Analyses and Stopping Rules', '49', '9.5', 'Outcomes', '49', '9.5.1', 'Primary Outcome', '49', '9.5.2', 'Secondary Outcomes', '49', '9.6', 'Data Analyses', '53', '10. DATA COLLECTION AND QUALITY ASSURANCE', '57', '10.1', 'Data Collection Forms', '57', '10.2', 'Data Management', '57', '10.3', 'Quality Assurance', '58', '10.3.1', 'Training', '58', '10.3.2', 'Quality Control Committee', '58', '10.3.3', 'Metrics', '58', '10.3.4', 'Protocol Deviations', '59', '10.3.5', 'Monitoring', '59', '11. PARTICIPANT RIGHTS AND CONFIDENTIALITY', '60', 'IMOVE Protocol, Version 6.0', '6 of 76']['11.1', 'Institutional Review Board (IRB) Review', '60', '11.2', 'Informed Consent Forms', '60', '11.3', 'Participant Confidentiality', '61', '11.4', 'Study Discontinuation', '61', '12. COMMITTEES', '61', '13. PUBLICATION OF RESEARCH FINDINGS', '62', '14. REFERENCES', '62', 'I. Procedures Schedule', 'II. Informed Consent Form Template', 'III. Other (add as many appendices as necessary)', 'IMOVE Protocol, Version 6.0', '7 of 76']\n\n###\n\n", "completion": "END"}